Julie M. Gastier‐Foster
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Tumors and Oncological Cases
- Genomic variations and chromosomal abnormalities
- Cancer, Hypoxia, and Metabolism
- Lymphoma Diagnosis and Treatment
- Genomics and Rare Diseases
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms
- Cancer-related molecular mechanisms research
- Chronic Lymphocytic Leukemia Research
- Renal and related cancers
- Cancer-related Molecular Pathways
- Prenatal Screening and Diagnostics
- Genetic factors in colorectal cancer
- Adolescent and Pediatric Healthcare
- Molecular Biology Techniques and Applications
- Glioma Diagnosis and Treatment
Baylor College of Medicine
2015-2025
Texas Children's Hospital
2020-2025
The Ohio State University Wexner Medical Center
2013-2024
Nationwide Children's Hospital
2014-2023
The Ohio State University
2014-2023
Children's Oncology Group
2006-2022
Arcadia
2006-2022
Van Andel Institute
2020
St. Jude Children's Research Hospital
2018-2019
National Cancer Institute
2015-2018
Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns and epigenetic phenotypes not yet clear. We analyzed genomes 200 clinically annotated adult cases de novo AML, using either whole-genome sequencing (50 cases) or whole-exome (150 cases), along with RNA microRNA DNA-methylation analysis. AML have fewer than most other cancers, an average only 13 found in genes. Of these, 5 genes recurrently mutated AML. A total...
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II III) have highly variable clinical behavior that is not adequately predicted on basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty compounded by interobserver variability in diagnosis. Mutations IDH, TP53, ATRX codeletion chromosome arms 1p 19q (1p/19q codeletion) been implicated as clinically relevant...
Liver cancer has the second highest worldwide mortality rate and limited therapeutic options. We analyzed 363 hepatocellular carcinoma (HCC) cases by whole-exome sequencing DNA copy number analyses, we 196 HCC methylation, RNA, miRNA, proteomic expression also. mutation analysis identified significantly mutated genes, including LZTR1, EEF1A1, SF3B1, SMARCA4. Significant alterations or downregulation hypermethylation in genes likely to result metabolic reprogramming (ALB, APOB, CPS1) were...
Survival for children and young adults with high-risk B-acute lymphoblastic leukemia has improved significantly, but 20% to 25% of patients are not cured. Children's Oncology Group study AALL0232 tested two interventions improve survival.Between January 2004 2011, enrolled 3,154 participants 1 30 years old newly diagnosed leukemia. By using a 2 × factorial design, 2,914 were randomly assigned receive dexamethasone (14 days) versus prednisone (28 during induction high-dose methotrexate...
Abstract There is incomplete understanding of genetic heterogeneity and clonal evolution during cancer progression. Here we use deep whole-exome sequencing to describe the architecture 20 pediatric B-acute lymphoblastic leukaemias from diagnosis relapse. We show that diversity comparable at relapse survival not associated with mutation burden. Six pathways were frequently mutated, NT5C2 , CREBBP WHSC1 TP53 USH2A NRAS IKZF1 mutations enriched Half had multiple subclonal in a pathway or gene...
Highlights•Multi-omics definition of four robust molecular TET subtypes associated with survival•Thymomas have the lowest mutational burden among adult cancers•Enrichment HRAS, NRAS, TP53, and recurrent GTF2I mutations are observed•Expression autoimmune targets aneuploidy links thymoma to myasthenia gravisSummaryThymic epithelial tumors (TETs) one rarest malignancies. Among TETs, is most predominant, characterized by a unique association diseases, followed thymic carcinoma, which less common...
Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System. Here, we validate a revised classifier using Risk System (INRGSS) and incorporate segmental chromosome aberrations (SCA) an additional genomic biomarker.
Background Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of oncogenic genes fusing PAX3 or PAX7 FOXO1 (P3F P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value PAX-FOXO1 fusion status. Methods Study participants were treated on COG protocol D9803 for intermediate risk ERMS using multi-agent chemotherapy,...